<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467686</url>
  </required_header>
  <id_info>
    <org_study_id>349441</org_study_id>
    <nct_id>NCT02467686</nct_id>
  </id_info>
  <brief_title>Breast Cancer, Sexuality and Black Cohosh</brief_title>
  <acronym>Cimicifuga</acronym>
  <official_title>Effects of Cimicifuga Racemosa L. Nutt Sexuality of Women With Breast Cancer Using Tamoxifen or Aromatase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irmandade da Santa Casa de Misericordia de Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Irmandade da Santa Casa de Misericordia de Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of
      women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the study will be recruited 60 women treated with breast cancer, using tamoxifen or
      aromatase inhibitor, are in menopause, hot flashes and has with or without sexual life. They
      will answer the questionnaires: Kupperman, World Health Organization Quality of Life (WHOQOL)
      and those sexually active will have Female Sexual Function Index (FSFI). The control group
      will have 30 patients using tamoxifen alone or inhibitor. The other group will have 30
      patients receiving tamoxifen or inhibitor and will start with 2 tablets per day of dry
      extract of Cimicifuga racemosa. They will be followed for 6 months and answer questionnaires
      at the first visit, 3-month and 6-month follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hot flashes (score of hot flashes)</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the score of hot flashes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual function (score of sexual function questionnaire (FSFI)</measure>
    <time_frame>3 months</time_frame>
    <description>Determine the score of sexual function questionnaire (FSFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function (score of sexual function questionnaire (FSFI)</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the score of sexual function questionnaire (FSFI)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life (questionnaire scores of quality of life (WHOQOL)</measure>
    <time_frame>3 months</time_frame>
    <description>Determine the questionnaire scores of quality of life (WHOQOL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (questionnaire scores of quality of life (WHOQOL)</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the questionnaire scores of quality of life (WHOQOL)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sexuality</condition>
  <arm_group>
    <arm_group_label>Cimicifuga racemosa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.
Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.
WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.
FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.
WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.
FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>WHOQOL questionnaire</intervention_name>
    <description>WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.</description>
    <arm_group_label>Cimicifuga racemosa</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>The World Health Organization Quality of Life</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>FSFI questionnaire</intervention_name>
    <description>FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.</description>
    <arm_group_label>Cimicifuga racemosa</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Female sexual function index (FSFI) questionnaire</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>kupperman scale</intervention_name>
    <description>Kupperman scale is a tool to help evaluate the severity of menopausal symptoms</description>
    <arm_group_label>Cimicifuga racemosa</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Blatt-Kupperman menopausal index</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimicifuga racemosa</intervention_name>
    <description>The Cimicifuga racemosa effects on the sexuality of women with Breast cancer</description>
    <arm_group_label>Cimicifuga racemosa</arm_group_label>
    <other_name>Black Cohosh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <description>The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen</description>
    <arm_group_label>Cimicifuga racemosa</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.</description>
    <arm_group_label>Cimicifuga racemosa</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>aromatase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menopausal women with breast cancer treated and using tamoxifen or aromatase
             inhibitor.

          -  With hot flashes and with or without active sexual life.

        Exclusion Criteria:

          -  Women did not have breast cancer

          -  do not use tamoxifen or aromatase inhibitor

          -  not in menopause and not have hot flashes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Black cohosh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade da Santa Casa Misericordia Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolina Macruz</last_name>
    <phone>+5511999141447</phone>
    <email>carolmacruz@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carolina Furtado Macruz</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01225001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Macruz</last_name>
      <phone>+5511999141447</phone>
      <email>carolmacruz@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Irmandade da Santa Casa de Misericordia de Sao Paulo</investigator_affiliation>
    <investigator_full_name>Carolina Furtado Macruz</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>When I have finished my recruitment and analysis of the results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

